Anika Therapeutics (ANIK) Interest Expenses (2012 - 2026)

Anika Therapeutics (ANIK) has 10 years of Interest Expenses data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Interest Expenses changed N/A year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $45.6 million, up 0.96% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.7 million, up from $1000.0 in the prior quarter.
• Over the last five years, Interest Expenses for ANIK reached as high as $45.1 million in Q4 2024 and fell as low as $1000.0 in Q2 2025.
• Historically, Interest Expenses has averaged $4.6 million across 5 years, with a median of $474000.0 in 2023.
• Across the five-year window, Interest Expenses surged 35449.61% in 2024 and plunged 100.0% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $9.4 million in 2022, then tumbled by 98.65% to $127000.0 in 2023, then jumped by 35449.61% to $45.1 million in 2024, then plunged by 100.0% to $1000.0 in 2025, then surged by 166500.0% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $1.7 million in Q1 2026, $1000.0 in Q4 2025, and $1000.0 in Q2 2025.